Clinical classification of obesity and implications for metabolic dysfunction-associated fatty liver disease and treatment
Y Ding, Q Deng, M Yang, H Niu, Z Wang… - … Syndrome and Obesity, 2023 - Taylor & Francis
Obesity, and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached
epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically …
epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically …
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
W Cai, R Zhang, Y Yao, Q Wu, J Zhang - Frontiers in public health, 2024 - frontiersin.org
Objective To systematically evaluate the efficacy and safety of a new hypoglycemic drug,
tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and …
tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and …
Adults with metabolically healthy overweight or obesity present more brown adipose tissue and higher thermogenesis than their metabolically unhealthy counterparts
Background There is a subset of individuals with overweight/obesity characterized by a
lower risk of cardiometabolic complications, the so-called metabolically healthy …
lower risk of cardiometabolic complications, the so-called metabolically healthy …
Metabolically healthy obesity, transition from metabolic healthy to unhealthy status, and carotid atherosclerosis
Q Huang, Z Liu, M Wei, J Feng, Q Huang… - Diabetes/Metabolism …, 2024 - Wiley Online Library
Background Evidence of the effects of metabolically healthy obesity (MHO) on
atherosclerosis is limited; the transition effects of metabolic health and obesity phenotypes …
atherosclerosis is limited; the transition effects of metabolic health and obesity phenotypes …
Biology and clinical use of glucagon-like-peptide-1 receptor agonists in vascular protection
Abstract Glucagon-like-peptide-1 receptor agonists (GLP1RA) are incretin agents initially
designed for the treatment of type 2 diabetes mellitus but due to pleiotropic actions are now …
designed for the treatment of type 2 diabetes mellitus but due to pleiotropic actions are now …
[HTML][HTML] Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma
Abstract Background Immune checkpoint inhibitors (ICIs) have improved survival outcomes
in melanoma. Studies exploring the correlations between body mass index (BMI), type 2 …
in melanoma. Studies exploring the correlations between body mass index (BMI), type 2 …
Impact of coronary artery calcium on mortality and cardiovascular events in metabolic syndrome and diabetes among younger adults
S Masrouri, MD Shapiro, D Khalili… - European Journal of …, 2024 - academic.oup.com
Aims Whether coronary artery calcium (CAC) testing in younger individuals with metabolic
syndrome (MetS) and diabetes mellitus (DM) helps predict cardiovascular disease (CVD) …
syndrome (MetS) and diabetes mellitus (DM) helps predict cardiovascular disease (CVD) …
Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum
Abstract Cardiovascular-kidney-metabolic (CKM) syndrome and chronic kidney disease
(CKD) are two significant comorbidities affecting a large proportion of the general population …
(CKD) are two significant comorbidities affecting a large proportion of the general population …
A novel risk factor for malignancy: albuminuria
Cancer is the second leading cause of death among the adult population following
cardiovascular diseases. Prevention and earlier diagnosis are among the cornerstones in …
cardiovascular diseases. Prevention and earlier diagnosis are among the cornerstones in …
Tirzepatide and potential use for metabolically healthy obesity
Metabolically healthy obesity or metabolically healthy overweight (MHO) is best described
as being absent of any major metabolic disorder or cardiovascular diseases such as type 2 …
as being absent of any major metabolic disorder or cardiovascular diseases such as type 2 …